

34. Auriemma RS, Pivonello R, De Martino MC et al. Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. *Eur J Endocrinol.* 2012;168(1):15-22.
35. De Martino MC, Auriemma RS, Brevetti G et al. The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. *J Endocrinol Invest.* 2010;33(9):663-670.
36. Pivonello R, Galderisi M, Auriemma RS, De Martino MC et al. Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. *J Clin Endocrinol Metab.* 2007;92(2):476-482.
37. Kuhn E, Maione L, Bouchachi A et al. Long-term effects of pegvisomant on comorbidities in patients with acromegaly: retrospective single-center study. *Eur J Endocrinol.* 2015;173(5):693-702.
38. Auriemma RS, Grasso LF, Galdiero M, Galderisi M et al. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. *Endocrine.* 2016;55:872-884.
39. van der Lely AJ, Bernabeu I, Cap J et al. Co-administration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. *Eur J Endocrinol.* 2011;164:325-333.
40. Schreiber I, Buchfelder M, Droste M et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. *Eur J Endocrinol* 2007;156:75-82.
41. Neggers SJ, van Aken MO, Janssen JA et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. *J Clin Endocrinol Metab.* 2007;92:4598-4601.
42. Neggers SJ, Franck SE, de Rooij FW et al. Long term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogues in acromegaly. *J Clin Endocrinol Metab.* 2014;99:3644-3652.
43. Bernabeu I, Marazuela M, Lucas T et al. Pegvisomant-induced liver injury is related to the UGT1A1 *28 polymorphism of Gilbert's syndrome. *J Clin Endocrinol Metab* 2010;95:2147-2154.
44. Madsen M, Krusenstjerna-Hafstrom T, Moller L et al. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial. *J Clin Endocrinol Metab.* 2012;97:1227-1235.
45. Marazuela M, Paniagua AE, Gahete MD et al. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. *J Clin Endocrinol Metab.* 2011;96:E251-E259.
46. De Marinis L, Bonadonna S, Bianchi A et al. Primary empty sella. *J Clin Endocrinol Metab.* 2005;90:5471-5477.
47. Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. *J Clin Endocrinol Metab.* 2011; 96:1325-1335.
48. Melmed S, Colao A, Barkan A et al. Acromegaly Consensus Group. Guidelines for acromegaly management: an update. *J Clin Endocrinol Metab.* 2009;94:1509-1517.
49. Giustina A, Ambrosio MR, Beck Peccoz P et al. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. *J Endocrinol Invest.* 2014;37(10):1017-30.

Vzdělávejte se on-line a získejte kredity

**webináře
on-line kurzy
on-line kongresy**



**On-line vzdělávání
pro odborníky
ve zdravotnictví
na online.solen.cz**

SOLEN MEDICAL EDUCATION

- Akce jsou pořádány dle Stavovského předpisu ČLK č. 16 a jsou ohodnoceny v rámci postgraduálního vzdělávání **kredity pro lékaře**
- Přístup na většinu vzdělávacích akcí je **zdarma**
- Program připravujeme ve spolupráci s významnými osobnostmi medicíny a farmacie
- On-line kurzů se již zúčastnilo přes 13000 zdravotníků